• 1
    De Franchis R. Portal hypertension. Baveno III Consensus Statements. Primary prophylaxis. Session 5. Oxford: Blackwell Science, 2001:127131.
  • 2
    Groszmann RJ, Bosch J, Grace N, Conn HO, García-Tsao G, Navasa M, Alberts J, et al. Hemodynamic events in a prospective randomized trial of propranolol vs placebo in the prevention of the first variceal hemorrhage. Gastroenterology 1990; 99:14011407.
  • 3
    Feu F, García-Pagán JC, Bosch J, Luca A, Terés J, Escorcell A, Rodís J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995; 346:10561059.
  • 4
    Bosch J, García-Pagán JC, Feu F, Luca A. New approaches in the pharmacologic treatment of portal hypertension. J Hepatol 1993; 17(Suppl 2):S41S45.
  • 5
    Okumura H, Arakami T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, Terada H, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991; 86:4652.
  • 6
    García-Pagán J, Salmeron J, Feu F, Gines P, Pizcueta P, Claria J, Arroyo V, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19:10951099.
  • 7
    García-Pagán J, Salmeron J, Feu F, Gines P, Pizcueta P, Claria J, Arroyo V, et al. Plasma volume reduction by spironolactone decreases portal pressure in patients with compensated cirrhosis. Synergistic effect with propranolol [Abstract]. J Hepatol 1991; 13:530.
  • 8
    Sugano S, Kawafune T, Okajima T, Ishii K, Watanabe M, Takamura N. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 1998; 43:893897.
  • 9
    Nevens F, Lijnen P, VanBilloen H, Fevery J. The effects of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996; 23:10471052.
  • 10
    Colombato L, Albillos A, Groszmann R. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal hypertension rats. Hepatology 1992; 15:323328.
  • 11
    Schrier R, Arroyo V, Bernardi M, Epstein M, Henriksen J, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:11511157.
  • 12
    Dacquet C, Loirand G, Mironneau C, Mironneau J, Pacaud P. Spironolactone inhibition of contraction and calcium channels in rat portal vein. Br J Pharmacol 1987; 92:535544.
  • 13
    Japanese Research Society for Portal Hypertension. The general rules for recording endoscopic findings on esophageal varices. Jpn J Surg 1980; 10:8487.
  • 14
    Romero G, Kravetz D, Argonz J, Bildozola M, Suarez A, Terg R. Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients. J Hepatol 2000; 32:419425.
  • 15
    Van De Casteele M, Van Roel G, Nevens F, Fevery J. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology 1996; 24:14921496.
  • 16
    Oberti F, Pilette C, Rifflet H, Maiga MY, Moreau A, Gallois Y, Girault A, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997; 26:13631371.
  • 17
    Sugano S, Suzuki T, Nishio M, Makino H, Okajima T. Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin vs low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. Dig Dis Sci 1997; 42:529535.
  • 18
    Mironneau J. Calcium channel antagonist effects of spironolactone, an aldosterone antagonist. Am J Cardiol 1990; 65:7K8K.
  • 19
    Sogni P, Soupison T, Moreau R, Le Moine O, Bacq Y, Hadengue A, Lebrec D. Hemodynamic effects of acute administration of furosemide in patients with cirrhosis receiving β-adrenergic antagonist. J Hepatol 1994; 20:548552.
  • 20
    Genecin P, Polio J, Groszmann R. Na restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension. Am J Physiol 1990; 259:G498G503.
  • 21
    Conn HO, Lindenmuth WW, May CJ, Ramsby GR. Prophylactic portocaval anastomosis. A tale of two studies. Medicine 1972; 51:2740.
  • 22
    The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. J Hepatol 1989; 9:7583.
  • 23
    Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7:648653.
  • 24
    Gerbes A, Remien J, Jungst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986; 1:14091411.
  • 25
    Escorsell A, Ferayorni L, Bosch J, Garcia-Pagan JC, Garcia-Tsao G, Grace ND, Rodes J, et al. The portal pressure response to beta blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997; 112:20122016.
  • 26
    Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997; 113:16321639.
  • 27
    Merkel C, Marin R. Sacerdoti D, Donada C, Cavallarin G, Torboli P, Amodio P, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 31:324329.
  • 28
    Gines P. Uncomplicated ascites. International Ascites Club. Consensus Document. 5th Meeting. Dallas, TX: AASLD, 1999.